Ribonucleotide reductase metallocofactor: Assembly, maintenance and inhibition

Frontiers in Biology

Volumn 9, Issue 2, 2014, Pages 104-113

  Zhang, Caiguo ^a   Liu, Guoqi ^a   Huang, Mingxia ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

iron homeostasis; ribonucleotide reductase (RNR)

Indexed keywords

EID: 84897546355     PISSN: 16747984     EISSN: 16747992     Source Type: Journal    
DOI: 10.1007/s11515-014-1302-6     Document Type: Review

References (129)

1. Allen J B, Zhou Z, Siede W, Friedberg E C, Elledge S J (1994). The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev, 8(20): 2401-2415.
2. Atkin C L, Thelander L, Reichard P, Lang G (1973). Iron and free radical in ribonucleotide reductase. Exchange of iron and Mössbauer spectroscopy of the protein B2 subunit of the Escherichia coli enzyme. J Biol Chem, 248(21): 7464-7472.
3. Aye Y, Brignole E J, Long M J, Chittuluru J, Drennan C L, Asturias F J, Stubbe J (2012a). Clofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamers. Chem Biol, 19(7): 799-805.
4. Aye Y, Long M J, Stubbe J (2012b). Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species. J Biol Chem, 287(42): 35768-35778.
5. Barlow T, Eliasson R, Platz A, Reichard P, Sjöberg B M (1983). Enzymic modification of a tyrosine residue to a stable free radical in ribonucleotide reductase. Proc Natl Acad Sci USA, 80(6): 1492-1495.
6. Bianchi V, Pontis E, Reichard P (1986). Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem, 261(34): 16037-16042.
7. Björklund S, Skog S, Tribukait B, Thelander L (1990). S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry, 29(23): 5452-5458.
8. Boehmer P E, Lehman I R (1997). Herpes simplex virus DNA replication. Annu Rev Biochem, 66(1): 347-384.
9. Bollinger J M Jr, Edmondson D E, Huynh B H, Filley J, Norton J R, Stubbe J (1991). Mechanism of assembly of the tyrosyl radicaldinuclear iron cluster cofactor of ribonucleotide reductase. Science, 253(5017): 292-298.
10. Bollinger J M Jr, Jiang W, Green M T, Krebs C (2008). The manganese (IV)/iron(III) cofactor of Chlamydia trachomatis ribonucleotide reductase: structure, assembly, radical initiation, and evolution. Curr Opin Struct Biol, 18(6): 650-657.
11. Bollinger J M Jr, Tong W H, Ravi N, Huynh B H, Edmondson D E, Stubbe J A (1995). Use of rapid kinetics methods to study the assembly of the diferric-tyrosyl radical cofactor of E. coli ribonucleotide reductase. Methods Enzymol, 258: 278-303.
12. Brockman R W, Shaddix S, Laster W R Jr, Schabel F M Jr (1970). Inhibition of ribonucleotide reductase, DNA synthesis, and L1210 leukemia by guanazole. Cancer Res, 30(9): 2358-2368.
13. Burrell R A, McClelland S E, Endesfelder D, Groth P, Weller M C, Shaikh N, Domingo E, Kanu N, Dewhurst S M, Gronroos E, Chew S K, Rowan A J, Schenk A, Sheffer M, Howell M, Kschischo M, Behrens A, Helleday T, Bartek J, Tomlinson I P, Swanton C (2013). Replication stress links structural and numerical cancer chromosomal instability. Nature, 494(7438): 492-496.
14. Buss J L, Torti FM, Torti S V (2003). The role of iron chelation in cancer therapy. Curr Med Chem, 10(12): 1021-1034.
15. Cairns R A, Harris I S, Mak T W (2011). Regulation of cancer cell metabolism. Nat Rev Cancer, 11(2): 85-95.
16. Campestre C, Agamennone M, Tortorella P, Preziuso S, Biasone A, Gavuzzo E, Pochetti G, Mazza F, Hiller O, Tschesche H, Consalvi V, Gallina C (2006). N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8. Bioorg Med Chem Lett, 16(1): 20-24.
17. Cerqueira N M, Fernandes P A, Ramos M J (2007). Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Patents Anticancer Drug Discov, 2(1): 11-29.
18. Chabes A, Georgieva B, Domkin V, Zhao X, Rothstein R, Thelander L (2003a). Survival of DNA damage in yeast directly depends on increased dNTP levels allowed by relaxed feedback inhibition of ribonucleotide reductase. Cell, 112(3): 391-401.
19. Chabes A, Thelander L (2003). DNA building blocks at the foundation of better survival. Cell Cycle, 2(3): 171-173.
20. Chabes A L, Pfleger C M, Kirschner M W, Thelander L (2003b). Mouse ribonucleotide reductase R2 protein: a new target for anaphasepromoting complex-Cdh1-mediated proteolysis. Proc Natl Acad Sci USA, 100(7): 3925-3929.
21. Chabouté M E, Clément B, Philipps G (2002). S phase and meristemspecific expression of the tobacco RNR1b gene is mediated by an E2F element located in the 5′ leader sequence. J Biol Chem, 277(20): 17845-17851.
22. Chabouté M E, Clément B, Sekine M, Philipps G, Chaubet-Gigot N (2000). Cell cycle regulation of the tobacco ribonucleotide reductase small subunit gene is mediated by E2F-like elements. Plant Cell, 12(10): 1987-2000.
23. Chaston T B, Lovejoy D B, Watts R N, Richardson D R (2003). Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res, 9(1): 402-414.
24. Chaston T B, Richardson D R (2003). Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol, 73(3): 200-210.
25. Climent I, Sjöberg B M, Huang C Y (1991). Carboxyl-terminal peptides as probes for Escherichia coli ribonucleotide reductase subunit interaction: kinetic analysis of inhibition studies. Biochemistry, 30(21): 5164-5171.
26. Cotruvo J A Jr, Stubbe J (2010). An active dimanganese(III)-tyrosyl radical cofactor in Escherichia coli class Ib ribonucleotide reductase. Biochemistry, 49(6): 1297-1309.
27. Cotruvo J A Jr, Stubbe J (2011). Class I ribonucleotide reductases: metallocofactor assembly and repair in vitro and in vivo. Annu Rev Biochem, 80(1): 733-767.
28. Coves J, Zeghouf M, Macherel D, Guigliarelli B, Asso M, Fontecave M (1997). Flavin mononucleotide-binding domain of the flavoprotein component of the sulfite reductase from Escherichia coli. Biochemistry, 36(19): 5921-5928.
29. D'Angiolella V, Donato V, Forrester FM, Jeong Y T, Pellacani C, Kudo Y, Saraf A, Florens L, Washburn M P, Pagano M (2012). Cyclin Fmediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell, 149(5): 1023-1034.
30. Davies B W, Kohanski M A, Simmons L A, Winkler J A, Collins J J, Walker G C (2009). Hydroxyurea induces hydroxyl radical-mediated cell death in Escherichia coli. Mol Cell, 36(5): 845-860.
31. Dayani P N, Bishop M C, Black K, Zeltzer P M (2004). Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol, 67(3): 367-377.
32. Donehower R C (1992). An overview of the clinical experience with hydroxyurea. Semin Oncol, 19(3 Suppl 9): 11-19.
33. Eklund H, Uhlin U, Färnegårdh M, Logan D T, Nordlund P (2001). Structure and function of the radical enzyme ribonucleotide reductase. Prog Biophys Mol Biol, 77(3): 177-268.
34. Elledge S J, Zhou Z, Allen J B, Navas TA (1993). DNA damage and cell cycle regulation of ribonucleotide reductase. BioEssays, 15: 333-339.
35. Enyedy E A, Primik M F, Kowol C R, Arion V B, Kiss T, Keppler B K (2011). Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study. Dalton Trans, 40(22): 5895-5905.
36. Fan H, Villegas C, Huang A, Wright J A (1998). The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res, 58(8): 1650-1653.
37. Finch R A, Liu MC, Cory A H, Cory J G, Sartorelli A C (1999). Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul, 39(1): 3-12.
38. Fishbein WN, Carbone P P (1963). Hydroxyurea: Mechanism of Action. Science, 142(3595): 1069-1070.
39. Fontecave M, Eliasson R, Reichard P (1987). NAD(P)H: flavin oxidoreductase of Escherichia coli. A ferric iron reductase participating in the generation of the free radical of ribonucleotide reductase. J Biol Chem, 262(25): 12325-12331.
40. Fontecave M, Eliasson R, Reichard P (1989). Enzymatic regulation of the radical content of the small subunit of Escherichia coli ribonucleotide reductase involving reduction of its redox centers. J Biol Chem, 264(16): 9164-9170.
41. Fontecave M, Mulliez E, Logan D T (2002). Deoxyribonucleotide synthesis in anaerobic microorganisms: the class III ribonucleotide reductase. Prog Nucleic Acid Res Mol Biol, 72: 95-127.
42. Gwilt P R, Tracewell W G (1998). Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet, 34(5): 347-358.
43. Halimi Y, Dessau M, Pollak S, Ast T, Erez T, Livnat-Levanon N, Karniol B, Hirsch J A, Chamovitz D A (2011). COP9 signalosome subunit 7 from Arabidopsis interacts with and regulates the small subunit of ribonucleotide reductase (RNR2). Plant Mol Biol, 77(1-2): 77-89.
44. Hanahan D, Weinberg R A (2011). Hallmarks of cancer: the next generation. Cell, 144(5): 646-674.
45. Hao Z, Qiao T, Jin X, Li X, Gao J, Fan D (2005). Preparation and characterization of a specific monoclonal antibody against CIAPIN1. Hybridoma (Larchmt), 24(3): 141-145.
46. Harper J W, Elledge S J (2007). The DNA damage response: ten years after. Mol Cell, 28(5): 739-745.
47. Haunhorst P, Hanschmann E M, Bräutigam L, Stehling O, Hoffmann B, Mühlenhoff U, Lill R, Berndt C, Lillig C H (2013). Crucial function of vertebrate glutaredoxin 3 (PICOT) in iron homeostasis and hemoglobin maturation. Mol Biol Cell, 24(12): 1895-1903.
48. Hofer A, Crona M, Logan D T, Sjöberg B M (2012). DNA building blocks: keeping control of manufacture. Crit Rev Biochem Mol Biol, 47(1): 50-63.
49. Hristova D, Wu C H, Jiang W, Krebs C, Stubbe J (2008). Importance of the maintenance pathway in the regulation of the activity of Escherichia coli ribonucleotide reductase. Biochemistry, 47(13): 3989-3999.
50. Hu C M, Yeh M T, Tsao N, Chen C W, Gao Q Z, Chang C Y, Lee M H, Fang J M, Sheu S Y, Lin C J, Tseng M C, Chen Y J, Chang Z F (2012). Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. Cancer Cell, 22(1): 36-50.
51. Huang M, Elledge S J (1997). Identification of RNR4, encoding a second essential small subunit of ribonucleotide reductase in Saccharomyces cerevisiae. Mol Cell Biol, 17(10): 6105-6113.
52. Jiang W, Yun D, Saleh L, Barr E W, Xing G, Hoffart L M, Maslak M A, Krebs C, Bollinger JM Jr (2007). A manganese(IV)/iron(III) cofactor in Chlamydia trachomatis ribonucleotide reductase. Science, 316(5828): 1188-1191.
53. Johns D G, Gao W Y (1998). Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol, 55(10): 1551-1556.
54. Jordan A, Reichard P (1998). Ribonucleotide reductases. Annu Rev Biochem, 67(1): 71-98.
55. Kaplan J, McVey Ward D, Crisp R J, Philpott C C (2006). Irondependent metabolic remodeling in S. cerevisiae. Biochim Biophys Acta, 1763(7): 646-651.
56. Kashlan O B, Cooperman B S (2003). Comprehensive model for allosteric regulation of mammalian ribonucleotide reductase: refinements and consequences. Biochemistry, 42(6): 1696-1706.
57. Ke P Y, Kuo Y Y, Hu C M, Chang Z F (2005). Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability. Genes Dev, 19(16): 1920-1933.
58. Kennedy B J (1992). The evolution of hydroxyurea therapy in chronic myelogenous leukemia. Semin Oncol, 19(3 Suppl 9): 21-26.
59. Kolberg M, Strand K R, Graff P, Andersson K K (2004). Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta, 1699(1-2): 1-34.
60. Kumar D, Viberg J, Nilsson A K, Chabes A (2010). Highly mutagenic and severely imbalanced dNTP pools can escape detection by the Sphase checkpoint. Nucleic Acids Res, 38(12): 3975-3983.
61. Kunkel T A, Silber J R, Loeb L A (1982). The mutagenic effect of deoxynucleotide substrate imbalances during DNA synthesis with mammalian DNA polymerases. Mutat Res, 94(2): 413-419.
62. Kunos C, Radivoyevitch T, Abdul-Karim F W, Fanning J, Abulafia O, Bonebrake A J, Usha L (2012). Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. J Transl Med, 10(1): 79.
63. Kurita J, Nakajima K (2012). Megalocytiviruses. Viruses, 4(4): 521-538.
64. Lassmann G, Thelander L, Gräslund A (1992). EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea. Biochem Biophys Res Commun, 188(2): 879-887.
65. Lee Y D, Wang J, Stubbe J, Elledge S J (2008). Dif1 is a DNA-damageregulated facilitator of nuclear import for ribonucleotide reductase. Mol Cell, 32(1): 70-80.
66. Lill R, Hoffmann B, Molik S, Pierik A J, Rietzschel N, Stehling O, Uzarska M A, Webert H, Wilbrecht C, Mühlenhoff U (2012). The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta, 1823(9): 1491-1508.
67. Liu C, Powell K A, Mundt K, Wu L, Carr A M, Caspari T (2003). Cop9/signalosome subunits and Pcu4 regulate ribonucleotide reductase by both checkpoint-dependent and-independent mechanisms. Genes Dev, 17(9): 1130-1140.
68. Liu X, Zhou B, Xue L, Yen F, Chu P, Un F, Yen Y (2007). Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer, 6(5): 374-381.
69. Loeb L A, Kunkel T A (1982). Fidelity of DNA synthesis. Annu Rev Biochem, 51(1): 429-457.
70. Logan D T, Mulliez E, Larsson K M, Bodevin S, Atta M, Garnaud P E, Sjoberg B M, Fontecave M (2003). A metal-binding site in the catalytic subunit of anaerobic ribonucleotide reductase. Proc Natl Acad Sci USA, 100(7): 3826-3831.
71. Lovejoy D B, Richardson D R (2003). Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem, 10(12): 1035-1049.
72. Madaan K, Kaushik D, Verma T (2012). Hydroxyurea: a key player in cancer chemotherapy. Expert Rev Anticancer Ther, 12(1): 19-29.
73. Mathews C K (2006). DNA precursor metabolism and genomic stability. FASEB J, 20: 1300-1314.
74. Mayhew C N, Sumpter R, Inayat M, Cibull M, Phillips J D, Elford H L, Gallicchio V S (2005). Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirusinduced lymphoproliferative disease. Antiviral Res, 65(1): 13-22.
75. Minnihan E C, Ando N, Brignole E J, Olshansky L, Chittuluru J, Asturias F J, Drennan C L, Nocera D G, Stubbe J (2013a). Generation of a stable, aminotyrosyl radical-induced α2β2 complex of Escherichia coli class Ia ribonucleotide reductase. Proc Natl Acad Sci USA, 110(10): 3835-3840.
76. Minnihan E C, Nocera D G, Stubbe J (2013b). Reversible, long-range radical transfer in E. coli class Ia ribonucleotide reductase. Acc Chem Res, 46(11): 2524-2535.
77. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin J D (1997). Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol, 41(3): 404-407.
78. Mowa M B, Warner D F, Kaplan G, Kana B D, Mizrahi V (2009). Function and regulation of class I ribonucleotide reductase-encoding genes in mycobacteria. J Bacteriol, 191(3): 985-995.
79. Mühlenhoff U, Molik S, Godoy J R, Uzarska MA, Richter N, Seubert A, Zhang Y, Stubbe J, Pierrel F, Herrero E, Lillig C H, Lill R (2010). Cytosolic monothiol glutaredoxins function in intracellular iron sensing and trafficking via their bound iron-sulfur cluster. Cell Metab, 12(4): 373-385.
80. Nakano K, Bálint E, Ashcroft M, Vousden K H (2000). A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene, 19(37): 4283-4289.
81. Netz D J, Stümpfig M, Doré C, Mühlenhoff U, Pierik A J, Lill R (2010). Tah18 transfers electrons to Dre2 in cytosolic iron-sulfur protein biogenesis. Nat Chem Biol, 6(10): 758-765.
82. Niida H, Katsuno Y, Sengoku M, Shimada M, Yukawa M, Ikura M, Ikura T, Kohno K, Shima H, Suzuki H, Tashiro S, Nakanishi M (2010). Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase. Genes Dev, 24(4): 333-338.
83. Nordlund P, Reichard P (2006). Ribonucleotide reductases. Annu Rev Biochem, 75(1): 681-706.
84. Nyholm S, Thelander L, Gräslund A (1993). Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry, 32(43): 11569-11574.
85. Offenbacher A R, Vassiliev I R, Seyedsayamdost MR, Stubbe J, Barry B A (2009). Redox-linked structural changes in ribonucleotide reductase. J Am Chem Soc, 131(22): 7496-7497.
86. Ormö M, deMaré F, Regnström K, Aberg A, Sahlin M, Ling J, Loehr T M, Sanders-Loehr J, Sjöberg BM (1992). Engineering of the iron site in ribonucleotide reductase to a self-hydroxylating monooxygenase. J Biol Chem, 267(13): 8711-8714.
87. Ortigosa A D, Hristova D, Perlstein D L, Zhang Z, Huang M, Stubbe J (2006). Determination of the in vivo stoichiometry of tyrosyl radical per betabeta' in Saccharomyces cerevisiae ribonucleotide reductase. Biochemistry, 45(40): 12282-12294.
88. Pollycove M, Maqsood M (1962). Existence of an erythropoietic labile iron pool in animals. Nature, 194(4824): 152-154.
89. Pujol-Carrion N, Belli G, Herrero E, Nogues A, de la Torre-Ruiz M A (2006). Glutaredoxins Grx3 and Grx4 regulate nuclear localisation of Aft1 and the oxidative stress response in Saccharomyces cerevisiae. J Cell Sci, 119(Pt 21): 4554-4564.
90. Reece S Y, Hodgkiss J M, Stubbe J, Nocera D G (2006). Proton-coupled electron transfer: the mechanistic underpinning for radical transport and catalysis in biology. Philos Trans R Soc Lond B Biol Sci, 361(1472): 1351-1364.
91. Reichard P (1988). Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem, 57(1): 349-374.
92. Reichard P (1993). From RNA to DNA, why so many ribonucleotide reductases? Science, 260(5115): 1773-1777.
93. Ren S, Wang R, Komatsu K, Bonaz-Krause P, Zyrianov Y, McKenna C E, Csipke C, Tokes Z A, Lien E J (2002). Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. J Med Chem, 45(2): 410-419.
94. Richardson D R, Kalinowski D S, Richardson V, Sharpe P C, Lovejoy D B, Islam M, Bernhardt P V (2009). 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem, 52(5): 1459-1470.
95. Rofougaran R, Vodnala M, Hofer A (2006). Enzymatically active mammalian ribonucleotide reductase exists primarily as an alpha6-beta2 octamer. J Biol Chem, 281(38): 27705-27711.
96. Rouault T, Klausner R (1997). Regulation of iron metabolism in eukaryotes. Curr Top Cell Regul, 35: 1-19.
97. Saito Y, Shibayama H, Tanaka H, Tanimura A, Matsumura I, Kanakura Y (2011). PICOT is a molecule which binds to anamorsin. Biochem Biophys Res Commun, 408(2): 329-333.
98. Saldivar J C, Miuma S, Bene J, Hosseini S A, Shibata H, Sun J, Wheeler L J, Mathews C K, Huebner K (2012). Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet, 8(11): e1003077.
99. Salowe S, Bollinger J M Jr, Ator M, Stubbe J, McCraken J, Peisach J, Samano M C, Robins M J (1993). Alternative model for mechanismbased inhibition of Escherichia coli ribonucleotide reductase by 2′-azido-2′-deoxyuridine 5′-diphosphate. Biochemistry, 32(47): 12749-12760.
100. Sanvisens N, de Llanos R, Puig S (2013). Function and regulation of yeast ribonucleotide reductase: cell cycle, genotoxic stress, and iron bioavailability. Biomed J, 36: 51-58.
101. Scozzafava A, Supuran C T (2003). Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg Med Chem, 11(10): 2241-2246.
102. Shao J, Liu X, Zhu L, Yen Y (2013). Targeting ribonucleotide reductase for cancer therapy. Expert Opin Ther Targets, 17(12): 1423-1437.
103. Shao J, Zhou B, Di Bilio A J, Zhu L, Wang T, Qi C, Shih J, Yen Y (2006). A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther, 5(3): 586-592.
104. Shao J, Zhou B, Zhu L, Qiu W, Yuan Y C, Xi B, Yen Y (2004). In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res, 64(1): 1-6.
105. Shibayama H, Takai E, Matsumura I, Kouno M, Morii E, Kitamura Y, Takeda J, Kanakura Y (2004). Identification of a cytokine-induced antiapoptotic molecule anamorsin essential for definitive hematopoiesis. J Exp Med, 199(4): 581-592.
106. Sjöberg B M, Reichard P (1977). Nature of the free radical in ribonucleotide reductase from Escherichia coli. J Biol Chem, 252(2): 536-541.
107. Song S, Pursell Z F, Copeland WC, Longley MJ, Kunkel T A, Mathews C K (2005). DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci USA, 102(14): 4990-4995.
108. Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R (2008). Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer, 98(10): 1710-1715.
109. Stubbe J (2003). Di-iron-tyrosyl radical ribonucleotide reductases. Curr Opin Chem Biol, 7(2): 183-188.
110. Stubbe J, Cotruvo J A Jr (2011). Control of metallation and active cofactor assembly in the class Ia and Ib ribonucleotide reductases: diiron or dimanganese? Curr Opin Chem Biol, 15(2): 284-290.
111. Stubbe J, Ge J, Yee C S (2001). The evolution of ribonucleotide reduction revisited. Trends Biochem Sci, 26(2): 93-99.
112. Stubbe J, van Der Donk W A (1998). Protein Radicals in Enzyme Catalysis. Chem Rev, 98(2): 705-762.
113. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature, 404(6773): 42-49.
114. Thelander L, Gräslund A, Thelander M (1983). Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem Biophys Res Commun, 110(3): 859-865.
115. Wang J, Lohman G J, Stubbe J (2007). Enhanced subunit interactions with gemcitabine-5′-diphosphate inhibit ribonucleotide reductases. Proc Natl Acad Sci USA, 104(36): 14324-14329.
116. White M F, Dillingham M S (2012). Iron-sulphur clusters in nucleic acid processing enzymes. Curr Opin Struct Biol, 22(1): 94-100.
117. Willing A, Follmann H, Auling G (1988). Ribonucleotide reductase of Brevibacterium ammoniagenes is a manganese enzyme. Eur J Bio, 170: 603-611.
118. Wu C H, Jiang W, Krebs C, Stubbe J (2007). YfaE, a ferredoxin involved in diferric-tyrosyl radical maintenance in Escherichia coli ribonucleotide reductase. Biochemistry, 46(41): 11577-11588.
119. Wu X, Huang M (2008). Dif1 controls subcellular localization of ribonucleotide reductase by mediating nuclear import of the R2 subunit. Mol Cell Biol, 28(23): 7156-7167.
120. Xue L, Zhou B, Liu X, Qiu W, Jin Z, Yen Y (2003). Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res, 63(5): 980-986.
121. Yang F D, Spanevello R A, Celiker I, Hirschmann R, Rubin H, Cooperman B S (1990). The carboxyl terminus heptapeptide of the R2 subunit of mammalian ribonucleotide reductase inhibits enzyme activity and can be used to purify the R1 subunit. FEBS Lett, 272(1-2): 61-64.
122. Yao R, Zhang Z, An X, Bucci B, Perlstein D L, Stubbe J, Huang M (2003). Subcellular localization of yeast ribonucleotide reductase regulated by the DNA replication and damage checkpoint pathways. Proc Natl Acad Sci USA, 100(11): 6628-6633.
123. Ye H, Rouault T A (2010). Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease. Biochemistry, 49(24): 4945-4956.
124. Yen Y, Grill S P, Dutschman G E, Chang C N, Zhou B S, Cheng Y C (1994). Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res, 54(14): 3686-3691.
125. Yu Y, Wong J, Lovejoy D B, Kalinowski D S, Richardson D R (2006). Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res, 12(23): 6876-6883.
126. Zeidner J F, Karp J E, Blackford A L, Smith B D, Gojo I, Gore S D, Levis M J, Carraway H E, Greer J M, Ivy S P, Pratz K W, McDevitt M A (2013). Phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica, Zhang Y, Liu L, Wu X, An X, Stubbe J, Huang M (2011). Investigation of in vivo diferric tyrosyl radical formation in Saccharomyces cerevisiae Rnr2 protein: requirement of Rnr4 and contribution of Grx3/4 AND Dre2 proteins. J Biol Chem, 286(48): 41499-41509.
127. Zhang Y, Lyver E R, Nakamaru-Ogiso E, Yoon H, Amutha B, Lee DW, Bi E, Ohnishi T, Daldal F, Pain D, Dancis A (2008). Dre2, a conserved eukaryotic Fe/S cluster protein, functions in cytosolic Fe/S protein biogenesis. Mol Cell Biol, 28(18): 5569-5582.
128. Zhao X, Chabes A, Domkin V, Thelander L, Rothstein R (2001). The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 kinase cascade during growth and in response to DNA damage. EMBO J, 20(13): 3544-3553.
129. Zuckerman J E, Hsueh T, Koya R C, Davis ME, Ribas A (2011). siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol, 131(2): 453-460.